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ABSTRACT Antimicrobial susceptibility test results for trimethoprim-sulfadiazine with
Streptococcus equi subspecies are interpreted based on human data for trimetho-
prim-sulfamethoxazole. The veterinary-speciﬁc data generated in this study support
a single breakpoint for testing trimethoprim-sulfamethoxazole and/or trimethoprim-
sulfadiazine with S. equi. This study indicates trimethoprim-sulfamethoxazole as an
acceptable surrogate for trimethoprim-sulfadiazine with S. equi.
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Trimethoprim-sulfadiazine (SXD) is one of the antimicrobial agents prescribed for thetreatment of strangles and other equine infections caused by Streptococcus equi
subsp. equi and Streptococcus equi subsp. zooepidemicus (1). The CLSI veterinary stan-
dard (VET01-A4) lists breakpoints for trimethoprim-sulfamethoxazole (SXT) for Strepto-
coccus pneumoniae species, but not for SXD and beta-hemolytic streptococci (2).
Additionally, these breakpoints are based on human-derived data (3). Therefore, the
interpretation of antimicrobial susceptibility test (AST) results in compliance with CLSI
for S. equi is based on the clinical breakpoint for Streptococcus pneumoniae with SXT
used in human medicine (susceptible [S]  0.5/9.5 g/ml, intermediate [I]  1/19 to
2/38 g/ml, resistant [R]  4/76 g/ml and S  19 mm, I  16 to 18 mm, R  15 mm)
(2, 3). This breakpoint may not be appropriate for equine isolates due to the pharma-
cokinetic/pharmacodynamic (PK/PD) differences of the trimethoprim-sulfonamide com-
binations between horses and humans and because of the PK/PD variability of different
potentiated sulfonamide combinations on different bacterial species, sometimes even
within the same genus (4). There is limited information on the susceptibility of S. equi
subspecies to both SXT and SXD. Moreover, SXT is used as a class representative for
susceptibility testing of SXD by veterinary diagnostic laboratories, but this use has not
been validated speciﬁcally for equine isolates (2). This study had four goals: (i) deter-
mine if SXT is an acceptable surrogate drug for SXD when testing equine streptococcal
isolates; (ii) assess the in vitro activity of SXD and SXT against clinical isolates of S. equi;
(iii) evaluate the synergistic ratios for SXD and SXT with equine S. equi; and (iv) evaluate
whether the human breakpoints are appropriate for use with equine isolates.
(This study was presented in part at the 57th Annual Conference of the American
Association of Veterinary Laboratory Diagnosticians, Kansas City, MO, 16 to 22 October
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2014 [5] and the International Conference on One Health Antimicrobial Resistance,
Copenhagen, Denmark, 30 September to 2 October 2015 [6]).
A total of 270 S. equi isolates divided equally between S. equi subsp. equi (n  135)
and S. equi subsp. zooepidemicus (n  135) isolated from clinical cases of strangles or
equine infectious respiratory disease were used in the study. All isolates were collected
from laboratories participating in the Zoetis Global Therapeutics Research surveillance
program (2002 to 2009) from different geographic locations (USA [n  156], Canada
[n  94], and Europe [n  20]).
Minimal inhibitory concentration (MIC) as determined by the broth microdilution
procedure and agar disk diffusion tests were conducted (n  270) as previously
described (2, 7). SXT disks (1.25/23.75 g) (Oxoid Ltd.) were used in the disk diffusion
assay. MICs were determined for sulfadiazine (SDZ), sulfamethoxazole (SMX), trim-
ethoprim (TMP), and their corresponding TMP-sulfa combinations (1:19 ratio) (Sigma-
Aldrich). Quality control was conducted using CLSI-recommended quality control
strains (for MIC assay, Enterococcus faecalis American Type Culture Collection [ATCC]
29212, Streptococcus pneumoniae ATCC 49619, and Staphylococcus aureus ATCC 29213;
for disk diffusion assay, E. faecalis ATCC 29212, S. pneumoniae ATCC 49619, S. aureus
ATCC 25923, and Escherichia coli ATCC 25922) and antimicrobial agents (SXT disks,
amoxicillin-clavulanic acid combination [2:1], SXT combination [1:19], and ampicillin).
Cation-adjusted Mueller-Hinton broth (CA-MHB) and cation-adjusted Mueller-Hinton agar
(CA-MHA) (Fisher Scientiﬁc) were prepared in-house as per the instructions of the manu-
facturer. Thymidine phosphorylase (200 U/liter) (Sigma-Aldrich) was added to all media
prior to use to make sure that the media were as thymidine-free and thymine-free as
possible. Lysed horse blood (2 to 5%) (Hema Resource) was added to CA-MHB, and sheep
blood (5%) (Cleveland Scientiﬁc) was added to CA-MHA used for Streptococcus species only.
Fractional inhibitory concentration (FIC) indices were determined using the check-
erboard technique to evaluate optimal drug ratios for synergy (FIC index of 0.5) on a
selection of isolates (10 S. equi subsp. zooepidemicus isolates and 10 S. equi subsp. equi
isolates) (8). These isolates were chosen on the basis of very poor activity of individual
sulfonamides (MIC 2,084 g/ml). Quality control included testing for synergy (amoxi-
cillin and clavulanic acid) and antagonism (sparﬂoxacin and chloramphenicol) repro-
FIG 1 Histograms of MIC distributions for TMP, SMX, SDZ, SXT, and SXD for 270 S. equi isolates. MIC values for SXT and SXD are plotted based on the TMP
concentration in each combination antimicrobial (TMP-to-sulfonamide combination ratio 1:19). The concentration ranges for SXT and SXD tested are 0.03/0.6
to 32/608 g/ml.
AST of Potentiated Sulfas against S. equis Journal of Clinical Microbiology
January 2017 Volume 55 Issue 1 jcm.asm.org 327
 o
n






ducibility in the reference S. aureus strain ATCC 29213 (9, 10). FIC indices were
determined by using the method described by Krogstad and Moellering (8).
The MIC results are summarized in Fig. 1. Poor activity was recorded against
individual drugs (MIC90 values of 8, 256, and 2,048 g/ml for TMP, SMX, and SDZ,
respectively). MICs of SXT (MIC90 of 0.25/4.8 g/ml) and SXD (MIC90 of 0.25/4.8 g/ml)
at a ratio 1:19 were recorded for all tested isolates. A bimodal distribution was noticed
with an epidemiological cutoff value of 1/19 g/ml for wild type for both SXT and
SXD (Fig. 1). Test error rates were determined by the standard error rate-bounded
method (11, 12) using the R statistical computing program (Frisbee Sailing 2013-09-25
version 3.0.2) to plot scattergrams.
The disk diffusion method remains one of the most frequently employed AST
method (13). One of the challenges of this method with potentiated sulfonamides is
testing for SXD susceptibility using SXT disks without knowing whether the latter is
representative (2). Veterinary-speciﬁc epidemiological cutoffs were set for both sub-
species. Based on the MIC (S  0.5/9.5 g/ml; I  1/19 to 2/38 g/ml, and R  4/76
g/ml) and test zone diameter (S  19 mm; I  16 to 18 mm, and R  15 mm) cutoffs,
the discrepancy rates were within the acceptable range (very major errors  1%, major
errors  3.5%, and minor errors  5%) (Fig. 2). SXT disks are therefore good surrogates
for AST of potentiated sulfonamides. Moreover, the scattergram for SXD MICs versus
SXT MICs showed that SXT is a suitable representative for SXD (R  0.85) (Fig. 3), with
the consideration that SXT may be more active by at least one twofold dilution (40.74%
[110/270]) (data not shown).
The FIC indices (for S. equi subsp. equi and S. equi subsp. zooepidemicus, SXT
FICindex average values of 0.333 and 0.335, respectively, and SXD FICindex average values of
0.321 and 0.381, respectively) showed synergy at a wide range of TMP-to-sulfonamide
ratios and concentrations (1:1 to 1:256) (see Table S1 in the supplemental material). The
current ﬁndings are in accordance with those from a similar study conducted on 59
different equine pathogens (5). Additionally, the results comply with those from a
susceptibility study by the agar dilution method where TMP and nine sulfonamide
combinations exhibited synergy against equine Salmonella enterica serovars (n 62) at
all tested TMP-to-sulfonamide ratios (1:1 to 1:160) for all tested sulfonamides, including
SDZ but not SMX (synergy recorded at all ratios except at the 1:1 ratio) (14). In human
medicine, potentiated sulfonamides are administered at a 1:5 TMP-to-sulfa ratio to
FIG 2 Scattergrams of (a) SXT MIC and (b) SXD MIC versus SXT (1.25/23.75 g) disk diffusion test zone diameter (in millimeters) for 270 S. equi isolates. Numbers
represent the numbers of isolates at each MIC/test zone diameter pair. The horizontal and vertical lines represent MIC and disk diffusion cutoffs, respectively.
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achieve the 1:20 plasma ratio required for clinical efﬁcacy. It has been shown in equine
practice that potentiated sulfonamides achieve the 1:20 plasma ratio and can be
regarded to as therapeutically effective for susceptible S. equi when administered at 5
mg of TMP/kg of body weight and 25 mg of SDZ/kg (1:5 ratio) with a dosing interval
of 12 h (15–19). The results support the available literature, since the FIC indices
showed synergy at a wide range of TMP-to-sulfonamide ratios and concentrations.
Overall, the data indicated low resistance ﬁgures (2.2%) for both subspecies
regardless of the AST method used (data not shown). Similarly, Schwarz et al.(20) have
also reported low resistance ﬁgures (0%). However, high resistance values have been
reported in the literature (25.9% and 42% for S. equi subsp. equi and 45.5% and 61.1%
for S. equi subsp. zooepidemicus [21, 22]). While the reasons for the discrepancies in
resistance levels are not known, test methodologies could account for some of these
differences, as it is well established that thymidine levels in the test media can diminish
the activity of sulfas resulting in false resistance (23). We recommend following the CLSI
guidelines to determine whether the conditions of the growth medium are satisfactory
and ensure that excessive thymidine levels are not present in the test medium (2).
On the basis of the data generated in this study, we propose that the current CLSI
interpretive criteria for S. pneumoniae (MIC cutoffs of S 0.5/9.5 g/ml, I 1/19 to 2/38
g/ml, and R  4/76 g/ml and test zone diameter cutoffs of S  19 mm, I  16 to 18
mm, and R  15 mm) are suitable for testing equine S. equi. In the absence of resistant
strains, we recommend veterinary-speciﬁc interpretive criteria for susceptible strains
only for testing SXT and SXD with equine streptococcal isolates (MIC cutoff of S 
0.5/9.5 g/ml and test zone diameter cutoff of S  19 mm).
In summary, the data generated in this study indicate that SXT is an appropriate
class representative for AST of SXD in S. equi subsp. The generated data are
consistent with the human-derived interpretative criteria for SXT with S. pneu-
FIG 3 Scattergram of SXD versus SXT MICs (in micrograms per milliliter) for the 270 S. equi isolates tested. The scattergram also shows
the linear regression with R  0.85. Numbers represent the numbers of isolates at each SXD/SXT MIC pair.
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moniae. On the basis of the generated data, we propose a single susceptible
breakpoint for testing SXT and SXD in S. equi strains: a MIC cutoff of 0.5/9.5 g/ml
and a zone diameter cutoff of 19 mm.
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